Clinical Trials Logo

Clinical Trial Summary

Primary objective: To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment. Secondary objectives: - To figure the proportion of patients with reduction of ADCT score by 5 points after 4, 12, and 24 weeks of treatment. - To figure the proportion of patients with ADCT score less than 7 at weeks 4, 12, and 24. - Assess the effectiveness of dupilumab in moderate to severe atopic dermatitis (AD) patients, using the severity score as routine practice SCORing Atopic Dermatitis (SCORAD). - To describe comorbidities related to type 2 inflammation. - To characterize the safety profile of dupilumab in the local Gulf population. - To evaluate treatment satisfaction in the local Gulf population.


Clinical Trial Description

24 weeks ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05214326
Study type Observational
Source Sanofi
Contact Trial Transparency email recommended (Toll free for US & Canada)
Phone 800-633-1610
Email [email protected]
Status Recruiting
Phase
Start date January 18, 2022
Completion date May 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT04135560 - A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants Phase 1
Active, not recruiting NCT03992417 - Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Recruiting NCT04718870 - Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis Phase 4
Recruiting NCT05235724 - A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
Active, not recruiting NCT03687359 - Observational Evaluation of Atopic Dermatitis in Pediatric Patients
Active, not recruiting NCT04823130 - Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis Phase 4
Active, not recruiting NCT03849716 - Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)